Despite a share price drop, Shanghai Rendu Biotechnology's P...
Despite a share price drop, Shanghai Rendu Biotechnology's P/S ratio is still high compared to industry peers, raising concerns due to its recent poor growth rate. If current medium-term revenue trends persist, it could significantly affect the share price, posing a risk to shareholders and potential investors.
![](https://pubimg-10000538.picsh.myqcloud.com/20220509000001703ac4e146760.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment